Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency

Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency

This prospective, Phase 3, open-label, study (EudraCT: 2016-001631-12) evaluated pharmacokinetic (PK) characteristics of 3-/4-weekly Privigen® (IgPro10, CSL Behring, King of Prussia, PA, USA) in Japanese patients with PID. PK parameters including serum trough immunoglobulin (IgG) level before next i...

Full description

Bibliographic Details
Main Authors: Tomohiro Morio, Gautam Baheti, Michael A. Tortorici, Jutta Hofmann, Mikhail A. Rojavin
Format: Article
Language:English
Published: Taylor & Francis Group 2019-10-01
Series:Immunological Medicine
Subjects:
privigen®
igpro10
primary immunodeficiency
pharmacokinetic analysis
japanese patients
Online Access:http://dx.doi.org/10.1080/25785826.2019.1700085

Internet

http://dx.doi.org/10.1080/25785826.2019.1700085

Similar Items